PBAC's latest decision on Nandrolone decanoate: Not recommended (2018). Considered for Treatment of osteoporosis as monotherapy where other treatments have failed, are not tolerated, or are contraindicated, with specialist advice confirming it is the only suitable treatment option.
PBAC outcome
Not recommended
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2018
Submissions
1
2018 → 2018
Eligible population
Patients with osteoporosis where other treatments have failed, are not tolerated, or are contraindicated, requiring specialist confirmation that this is the only suitable treatment option
Therapy area
Endocrinology
Line of therapy
Later-line
Evidence base
Other
Comparator
nandrolone decanoate pre-filled syringe
Economic model
Not modelled
ICER note
Minor submission with no economic comparison presented
Why PBAC said no
Reasons cited in the latest PSD: no clinical need for a new form of nandrolone decanoate on the PBS for osteoporosis treatment, little clinical benefit noted by RACGP, lack of clinical context in this setting